Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BP11 versus EU-approved Xolair in chronic spontaneous urticaria
2022-001745-20Phase 3Active
- Sponsor
- CuraTeQ Biologics
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omalizumab in chronic idiopathic urticaria (CIU) (2 arms), sponsored by CuraTeQ Biologics. Primary endpoint: Change from baseline in weekly Itch Severity Score (ISS7) at Week 12. Started Nov 2022; status: active.
02
Drugs
omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2022-001745-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001745-20.